Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-10-10
2006-10-10
Nickol, Gary B. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C530S316000
Reexamination Certificate
active
07118747
ABSTRACT:
AT4receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.
REFERENCES:
patent: 5219883 (1993-06-01), Koszyk et al.
patent: WO 03/011304A! (2003-02-01), None
Masino, J.A. (“Identification of the Angiotensin IV Receptor Antagonist, Norleual, as a Novel Inhibitor of Angiogenesis and Tumor Growth”, Dissertation Abstracts International, May 2003, vol. 64, No. 7B).
Harding Joseph W
Wright John W
Nickol Gary B.
Pacific Northwest Biotechnology Inc.
Seed IP Law Group PLLC
Washington State University Research Foundation
LandOfFree
AT4 receptor ligands as angiogenic, anti-angiogenic, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with AT4 receptor ligands as angiogenic, anti-angiogenic, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and AT4 receptor ligands as angiogenic, anti-angiogenic, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3705466